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RelatioNshiP BetweeN PRogRessioN-FRee suRvival (PFs) aNd oveRall 
suRvival (os) iN hoRmoNe ReCePtoR-Negative metastatiC BReast 
CaNCeR (mBC): a ComPaRative eFFeCtiveNess aNalysis usiNg liNked 
Claims, emR, aNd moRtality ReCoRds
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Objectives: FDA accelerated approvals for some chemotherapies used PFS as an OS 
surrogate. However, one mBC approval was revoked after OS gains were not observed 
post-approval. We compared PFS with OS by first-line (1L) chemotherapy using 
real world evidence from US mBC patients. MethOds: IMS Health Comprehensive 
Disease Records for Breast Cancer link IMS PharMetrics Plus, oncology EMRs, and 
Social Security Death Index. Female breast cancer patients (ICD-9-CM 174.x, 233.0) 
were selected with index metastasis (ICD-9-CM 196.x-198.x or EMR Stage IV) 
7/1/2006-3/31/2012, age ≥ 18, no HR overexpression, 1L chemotherapy (anthracy-
clines or txanes [AT] or new cytotoxic agents [NCA]), enrollment 180 days pre-index 
and ≥ 30 days post-index, and no other malignancies. PFS proxy was 1L duration; 
OS was measured until death or censoring (end of enrollment). Log-rank analysis 
compared PFS by 1L treatment. A Cox proportional hazards model assessed post-1L 
OS by 1L chemotherapy and duration, propensity for NCA vs. AT, HER2 status, and 
patient characteristics. Results: Of 845 mBC patients, 334 met study criteria (mean 
[SD] age= 51.7 [8.7] years, 20.4% HER2+). Propensity for NCA (n= 70) vs. AT (n= 264) 
increased with diabetes history (OR= 2.79, 95% CI 1.12-6.90) and higher pre-index 
health care expenditures (OR= 1.27, 95% CI 1.05-1.54). 1L NCAs were administered 
a mean (median) 195.2 (73.0) days (anthracyclines 53.5 [44.0], taxanes 122.2 [47.5], 
-2Log LR 54.3, 2 df, p< .0001). Cox regression estimated that 30 additional days of 
1L chemotherapy predicted slightly shorter post-1L OS (HR= 1.03, 95% CI 1.00-1.06); 
NCA (vs. AT) predicted stronger decreases in post-1L OS (HR= 2.32, 95% CI 1.11-4.86) 
despite propensity adjustment. cOnclusiOns: Duration of 1L chemotherapy, as 
a proxy for PFS, predicted slightly shorter post-1L OS. Choice of 1L chemotherapy 
was a stronger predictor of post-1L OS, adjusted for selection bias. Real world data 
suggests that PFS is a poor OS surrogate in mBC.
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Objectives: Phase 3 oncology clinical trials have had success rates of 41% 
(Djulbegovic, Arch Int Med 2008). Against this backdrop, context is needed on the 
magnitude of benefit to expect from future successful trials, and the interplay of 
cost. Recognizing the limitations of comparing results across trials and therapies, we 
assessed recent FDA solid tumor approvals showing overall survival (OS) benefit in a 
randomized trial. The objective of this analysis is to define the magnitude of benefit 
and cost of solid tumor therapies approved by FDA from 2009-2013 having phase 3 OS 
benefit. MethOds: A systematic review of CenterWatch FDA-Approved Drugs and 
FDA sNDA/sBLA databases was conducted. Inclusion criteria required FDA approval 
or efficacy supplement, with OS data published 2009-2013. Hazard ratio (HR) and 
absolute and relative gain in median OS were assessed. First month drug costs were 
determined for 4Q2013, using methods previously described by Bach (NEJM 2009). 
Agents intended to be administered for £ 6 weeks were excluded from the cost 
analysis. Limitations include omission of many agents that represent important 
advances yet did not demonstrate statistically significant OS benefit relative to a 
control arm. Results: 18 FDA approved agents across 25 indications for 9 tumor 
types were assessed. The mean HR (range) and the mean relative gain in median OS 
vs trial comparator was 0.702 (0.410-0.817) and 27.91% (11.9%-67.2%), respectively. 
Medians for each measure were 0.725 and 23.6%. Mean first month treatment costs 
were $12,601 ($5,881-$50,025) with median costs of $9,282. cOnclusiOns: Over the 
last 5 years, for FDA-approved agents for treatment of solid tumors, the magnitude 
of survival benefit, measured either as Hazard Ratio or relative gain in median OS, 
was 24-30%. This benefit, and first month costs of $9 - 13,000, may represent mid-
points of expected levels for future solid tumor agents.
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Objectives: To describe and characterize mCRC patients who received 3rd-line 
therapy and to investigate the association of patient outcomes and treatment pat-
terns in a real-world community oncology network. MethOds: This retrospective 
study utilized data from the iKnowMed™ database and billing claims. Eligibility cri-
teria included diagnosis of mCRC, initiation of 1st-line therapy between 1/1/2007 and 
6/30/2011, and initiation of 3rd-line therapy (defined as index date) before 6/30/2012. 
The key outcome was overall survival (OS). Kaplan-Meier and Cox proportional 
hazard models were used to characterize the distribution and predictors of out-
comes. Results: 757 patients were eligible for the study. The most common 3rd-line 
therapies were anti-EGFR-based (55.4%), oxaliplatin-based (13.6%), and capecitabine-
based (11.4%). OS was 8.0 (95% CI: 7.1-8.9), 8.8 (7.4-11.0), and 9.1 (6.9-11.2) months, 
respectively. Over half of patients were ≤ 65 years old (54.3%), male (55.2%), treated in 
the Southern region (61.8%), overweight/obese (56.6%), and the majority had an ECOG 
performance status ≤ 1 (78.7%). 51.8% of patients had prior comorbidities. The 5 most 
common comorbidities were hematologic, cardiovascular, gastrointestinal, neuro-
logic, and endocrine disease. KRAS testing rates at index date were 35.4% (wild-type 
26.3%, mutation 9.1%). Of KRASwild-type patients, 80.9% were treated with anti-EGFR-
based regimens which was consistent with NCCN recommendations. cOnclusiOns: 
This comparative effectiveness study in a real-world community setting shows that 
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Objectives: Personalized treatment for biomarker-specific breast cancer is a real-
ity. However, outcomes research has lagged behind due to lack of data sources 
capturing testing, results, and drug treatment. This study uses a new oncology elec-
tronic medical record (EMR) database to examine testing, documentation of results, 
and appropriate treatment among a cohort of women with breast cancer treated 
in community oncology practices. MethOds: The Truven Health MarketScan® 
Oncology EMR Database was used to select patients diagnosed with breast cancer 
between July 1, 2011 and September 30, 2013 who had at least 2 visits and known 
disease stage. Biomarker tests and results for estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) were observed 
along with patients’ drug treatment. Results: 57,660 women met inclusion cri-
teria. Documented biomarker testing varied by disease stage and test. ER testing 
was > 90% for women with stage I or II; 77% for stage IV patients. More than 86% 
of women with stage 0-III and 71% with stage IV had a PR test. HER2 testing was 
documented in 66% with stage 0, 77% with stage I-III, and 63% with stage IV. Overall, 
74%, 55%, and 2% of women who were ER positive, HER2 positive, and HER2 nega-
tive respectively received biomarker specific treatment. Treatment rates varied by 
disease stage, with > 80% of stage IV women receiving appropriate treatment for ER 
positive or HER2 positive cancer. Among HER2 negative stage IV women, appropri-
ate treatment was 16%. 6%, 12%, and 14% of patients respectively had a biomarker 
result that was not consistent with ER positive, HER2 positive, and HER2 negative 
treatment received. cOnclusiOns: Documentation of appropriate testing varied 
both by the type of test and disease stage. Quality improvement programs aimed 
at documentation as well as appropriate treatment may benefit patients treated in 
community oncology practice.
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Objectives: Many studies have demonstrated that depression is associated with 
poor adherence to treatment of various diseases. Previous research has shown 
inconsistent results regarding the impact of depression on mammography use 
behaviors. The objective of this study was to assess the relationship between 
women’s depression and mammography use. To MethOds: This cross-sectional 
study used data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS) 
and employed the Health Belief Model (HBM). The independent variable was the 
presence of depression. The dependent variable was mammogram use, which was 
defined based on the U.S. Preventive Services Task Force’s mammogram guidelines, 
categorized at three levels: 1) had never been screened, 2) had been screened, but not 
within two years, and 3) had been screened within two years. Multivariate ordinal 
logistic regressions were used for analyses. Results: An estimated population 
size of 45,578,030 women was included. Among this population, 23.02% of women 
reported the presence of a depressive disorder. A chi-square test showed a signifi-
cant relationship between mammogram use and depression (p< 0.001). The unad-
justed proportional odds ratio [95% CI] when comparing women with depression to 
women without depression on mammogram use was 0.81 [0.76, 0.86], which means 
that both the odds of ‘screened within two years’ versus the combined ‘screened, 
but not within two years’ and ‘never screened’ and the odds of combined ‘screened 
within two years’ and ‘screened, but not within two years’ versus ‘never screened’ 
were 0.81 times lower for women with depression when compared to women with-
out depression (p< 0.001). However, when demographic and HBM characteristics 
were held constant in the regression model, the adjusted proportional odds ratio 
[95% CI] (1.05 [0.97, 1.14]) was not significant (p= 0.197). cOnclusiOns: Depression 
itself was related to the underuse of mammography. However, after controlling 
for demographic and HBM characteristics, depression was not associated with the 
underuse of mammography.
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Objectives: Screening of colon, stomach, bladder, prostate cancers is very relevant 
to reduce mortality. The applicable diagnosis scheme doesn’t allow detecting tumor 
processes in the early stages, later diagnosis increases cost of the next treatment, 
reducing its effectiveness and declines the length and quality of life. MethOds: We 
proposed to improve diagnostics of colorectal and stomach cancer using one test; 
to apply the test for occult blood for urological field. Application of a combined test 
for determining hidden “high” and “low” bleeding in both fields displays this type 
of screening in a very interesting and economically appropriate rank. Rapid test 
for occult blood specific for human hemoglobin and transferrin is more sensitive, 
freely available in the pharmacy network, economically priced, easy to use and gives 
results on “cito”. Results: The first year results of the test use data are analyzed. 
Patients used tests purchased at their own expense. We’ve tested 88 patients for 
diagnosing possible colorectal and stomach cancer and 182 urological patients for 
diagnosing possible cancer of bladder and prostate. All 88 digestive patients test 
results for diagnosing possible colorectal and stomach cancer were negative; among 
182 tests of the urological patients we received 17 positive results, future diagnostics 
proved 7 Cr-cases and 1 with precancerous (is under control). Such data does not 
allow yet statistic analysis. cOnclusiOns: The project is under implementation. 
For 7 Cr-diagnosed patients the treatment allows almost twice increase of expected 
life time and the 8-th patient may become our first preventive Cr-case. Proved effi-
ciency of the screening algorithm would become a basis for changing the national 
standard of medical care in Lviv region and Ukraine in general.
